Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand
ConclusionsA weight reduction program can prevent cirrhosis and HCC occurrences, and dominates all other treatment options. Pioglitazone and vitamin E demonstrated a trend towards decreasing the number of cirrhosis and HCC cases.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Actos | Alcoholism | Cancer & Oncology | Carcinoma | Cirrhosis | Fatty Liver Disease (FLD) | Health Management | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Thailand Health | Urology & Nephrology | Vitamin E | Vitamins